MicroRNA responses to the genotoxic carcinogens aflatoxin B1 and benzo[a]pyrene in human HepaRG cells

Toxicological Sciences

Volumn 149, Issue 2, 2016, Pages 496-502

  Marrone, April K ^a   Tryndyak, Volodymyr ^a   Beland, Frederick A ^a   Pogribny, Igor P ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Aflatoxin B1; Benzo a pyrene; HepaRG cells; MicroRNA

Indexed keywords

AFLATOXIN B1; AFLATOXIN B2; BENZO[A]PYRENE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; MICRORNA; MICRORNA 122; MICRORNA 410; UNCLASSIFIED DRUG; CARCINOGEN; HEPATOCYTE NUCLEAR FACTOR 4; HNF4A PROTEIN, HUMAN; MIRN122 MICRORNA, HUMAN;

ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; ENVIRONMENTAL EXPOSURE; GENOTOXICITY; HEPARG CELL; HUMAN; HUMAN CELL; LIVER CELL; LIVER TOXICITY; PROTEIN EXPRESSION; REGULATORY MECHANISM; TOXIN STRUCTURE; CELL CULTURE; CHEMICALLY INDUCED; DOSE RESPONSE; LIVER TUMOR; PHYSIOLOGY;

AFLATOXIN B1; BENZO(A)PYRENE; CARCINOGENS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; LIVER NEOPLASMS; MICRORNAS;

EID: 84960079069     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfv253     Document Type: Article

References (44)

1. Bandiera, S., Pfeffer, S., Baumert, T. F., and Zeisel, M. B. (2015) miR-122-a key factor and therapeutic target in liver disease. J. Hepatol. 62, 448-457.
2. Benigni, R. (2014). Predicting the carcinogenicity of chemicals with alternative approaches: recent advances. Expert Opin. Drug Metab. Toxicol. 10, 1199-1208.
3. Brambilla, G., and Martelli, A. (2009) Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals. Mutat. Res. 681, 209-223.
4. Coulouarn, C., Factor, V. M., Andersen, J. B., Durkin, M. E., and Thorgeirsson, S. S. (2009) Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metatastatic properties. Oncogene 28, 3526-3536.
5. Deng, X.-G., Qiu, R.-L., Wu, Y.-H., Li, Z.-X., Xie, P., Zhang, J., Zhou, J.-J., Zeng, L.-X., Tang, J., Maharjan, A., et al. (2014) Overexpression of miR-122 promotes the hepatic differentiation and maturation of mouse ESCs through a miR-122/FoxA1/HNF4a-positive feedback loop. Liver Int. 34, 281-295.
6. Doctorova, T. Y., Yildirimman, R., Vinken, M., Vilardell, M., Vanhaecke, T., Gmuender, H., Bort, R., Brolen, G., Holmgren, G., Li, R., et al. (2013) Transcriptomic responses generated by hepatocarcinogens in a battery of liver-based in vitro models. Carcinogenesis 34, 1393-1402.
7. Gatti, D. M., Lu, L., Williams, R. W., Sun, W., Wright, F. A., Threadgill, D. W., and Rusyn, I. (2011) MicroRNA expression in the livers of inbred mice. Mutat. Res. 714, 126-133.
8. Gaylor, D. W. (2005) Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens? Regul. Toxicol. Pharmacol. 41, 128-133.
9. Gooderham, N. J., and Koufaris, C. (2014) Using microRNAs to predict and evaluate hepatic carcinogenic potential. Toxicol. Lett. 228, 127-132.
10. Guillouzo, A., Corlu, A., Aninat, C., Glaise, D., Morel, F., and Guguen-Guillouzo, C. (2007) The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 168, 66-73.
11. Hart, S. N., Li, Y., Nakamoto, K., Subileau, E.-a., Steen, D., and Zhong, X.-b. (2010) A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab. Dispos. 38, 988-994.
12. Huff, J. (1999) Long-term chemical carcinogenesis bioassays predict human cancer hazards. Issues, controversies, and uncertainties. Ann. N. Y. Acad. Sci. 895, 56-79.
13. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 92. (2010). Some Non-hererocyclic Polycyclic Aromatic Hydrocarbons and Some Related Exposures. IARC, Lyon, France, pp. 1-853.
14. Jennen, D. G. J., Magkoufopoulou, C., Ketelslegers, H. B., van Herwijnen, M. H. M., Kleinjans, J. C. S., and van Delft, J. H. M. (2010) Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol. Sci. 115, 66-79.
15. Jetten, M. J. A., Kleinjans, J. C. S., Claessen, S. M., Chesné, C., and van Delft, J. H. M. (2013) Baseline and genotoxic compound induced gene expression profiles in HepG2 and HepaRG compared to primary human hepatocytes. Toxicol. In Vitro 27, 2031-2040.
16. Judson, R., Richard, A., Dix, D., Houck, K., Elloumi, F., Martin, M., Cathey, T., Transue, T. R., Spencer, R., and Wolf, M. (2008) ACToR-Aggregated Computational Toxicology Resource. Toxicol. Appl. Pharmacol. 233, 7-13.
17. Judson, R., Richard, A., Dix, D. S., Houck, K., Martin, M., Kavlock, R., Dellarco, V., Henry, T., Holderman, T., Sayre, P., et al. (2009) The toxicity landscape for environmental chemicals. Environ. Health Perspect. 117, 685-695.
18. Kensler, T. W., Busby, W. F., Jr, Davidson, N. E., and Wogan, G. N. (1976). Effect of hepatocarcinogens on the binding of glucocorticoid-receptor complex in rat liver nuclei. Cancer Res. 36, 4647-4651.
19. Kleinstreuer, N. C., Yang, J., Berg, E. L., Knudsen, T. B., Richard, A. M., Martin, M. T., Reif, D. M., Judson, R. S., Polokoff, M., et al. (2014) Phenotypic screening of the ToxCAst chemical library to classify toxic and therapeutic mechanisms. Nat. Biotechnol. 32, 583-591.
20. Koufaris, C., Wright, J., Currie, R. A., and Gooderham, N. J. (2012) Hepatic microRNA profiles offer predictive and mechanistic insights after exposure to genotoxic and epigenetic carcinogens. Toxicol. Sci. 128, 532-543.
21. Kutay, H., Bai, S., Datta, J., Motiwala, T., Pogribny, I., Frankel, W., Jacob, S. T., and Ghoshal, K. (2006) Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell Biochem. 99, 671-678.
22. Labialle, S., Marty, V., Bortolin-Cavaillé, M.-L., Hoareau-Osman, M., Pradère, J.-P., Valet, P., Martin, P. G. P., and Cavaillé, J. (2014) The miR-379/miR-410 cluster at the imprinted Dlk1-Dio3 domain controls neonatal metabolic activation. EMBO J. 33, 2216-2230.
23. Lempiäinen, H., Couttet, P., Bolognani, F., Mü ller, A., Dubost, V., Luisier, R., Del Rio Espinola, A., Vitry, V., Unterberger, E. B., et al. (2013) Identification of Dlk1-Dio3 imprinted gene cluster noncoding RNAs as novel candidate biomarkers for liver tumor promotion. Toxicol. Sci. 131, 375-386.
24. Lewis, A. P., and Jopling, C. L. (2010) Regulation and biological function of the liver-specific miR-122. Biochem. Soc. Trans. 38, 1553-1557.
25. Li, Z.-Y., Xi, Y., Zhu, W.-N., Zeng, C., Zhang, Z.-Q., Guo, Z.-C., Hao, D.-L., Liu, G., Feng, L., Chen, H.-Z., et al. (2011) Positive regulation of hepatic miR-122 expression by HNF4a. J. Hepatol. 55, 602-611.
26. Luk, J. M., Burchard, J., Zhang, C., Liu, A. M., Wong, K. F., Shek, F. H., Lee, N. P., Fan, S. T., Poon, R. T., Ivanovska, I., et al. (2011) DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. J. Biol. Chem. 286, 30706-30713.
27. Marone, P. A., Hall, W. C., and Hayes A. W. (2014) Reassessing the two-year rodent carcinogenicity bioassay: a review of the applicability to human risk and current perspectives. Regul. Toxicol. Pharmacol. 68, 108-118.
28. Marrone, A. K., Shpyleva, S., Chappell, G., Tryndyak, V., Uehara, T., Tsuchiya, M., Beland, F. A., Rusyn, I., and Pogribny I. P. (2015) Differentially expressed microRNAs provide mechanistic insight into fibrosis-associated liver carcinogenesis in mice. Mol. Carcinogenesis, (in press).
29. Miyaaki, H., Ichikawa, T., Kamo, Y., Taura, N., Honda, T., Shibata, H., Milazzo, M., Fornari, F., Gramantieri, L., Bolondi, L., et al. (2014). Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int. 34, e302-e307.
30. Osimitz, T. G., Droege, W., Boobis, A. R., and Lake, B. G. (2013). Evaluation of the utility of the lifetime mouse bioassay in the identification of cancer hazards for humans. Food Chem. Toxicol. 60, 550-562.
31. Papaioannou, M. D., Koufaris, C., and Gooderham, N. J. (2014). The cooked meat-derived mammary carcinogen 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine (PhIP) elicits estrogenic-like microRNA responses in breast cancer cells. Toxicol. Lett. 229, 9-16.
32. Rogue, A., Lambert, C., Spire, C., Claude, N., and Guillouzo, A. (2012). Interindividual variability in gene expression profiles in human hepatocytes and comparison with HepaRG cells. Drug Metab. Dispos. 40, 151-158.
33. Schmittgen, T. D., and Livak, K. J. (2008) Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 3, 1101-1108.
34. Shih, K. K., Qin, L.-X., Tanner, E. J., Zhou, Q., Bisogna, M., Dao, F., Olvera, N., Viale, A., Barakat, R. R., and Levine, D. A. (2011) A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol. Oncol. 121, 444-450.
35. Strober, W. (2001) Trypan blue exclusion test of cell viability. Curr. Protoc. Immunol. Appendix 3B: A.3B.1-A.3B.2.
36. Swenson, D. H., Lin, J.-K., Miller, E. C., and Miller, J. A. (1977) Aflatoxin B1-2, 3-oxide as a probable intermediate in the covalent binding of aflatoxins B1 and B2 to rat liver DNA and ribosomal RNA in vivo. Cancer Res. 37, 172-181.
37. Takaki, Y., Saito, Y., Takasugi, A., Toshimitsu, K., Yamada, S., Muramatsu, T., Kimura, M., Sugiyama, K., Suzuki, H., Arai, E., et al. (2014) Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis. Cancer Sci. 105, 1254-1260.
38. Trebicka, J., Anadol, E., Elfimova, N., Strack, I., Roggendorf, M., Viazov, S., Wedemeyer, I., Drebber, U., Rockstroh, J., Sauerbruch, T., et al. (2013) Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J. Hepatol. 58, 234-239.
39. Tsai, W.-C., Hsu, S.-D., Hsu, C.-S., Lai, T.-C., Chen, S.J., Shen, R., Hung, Y., Chen, H.-C., Lee, C.-H., Tsai, T.-F., et al. (2012) MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Invest. 122, 2884-2897.
40. Waidmann, O., Kö berle, V., Brunner, F., Zeuzem, S., Piiper, A., and Kronenberger, B. (2012) Serum microRNA-122 predicts survival in patients with liver cirrhosis. PLoS One 7, e45652.
41. Wang, S., Qiu, L., Yan, X., Jin, W., Wang, Y., Chen, L., Wu, E., Ye, X., Gao, G. F., Wang, F., et al. (2012) Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G1-modulated p53 activity. Hepatology 55, 730-741.
42. Wang, Y., Fu, J., Jiang, M., Zhang, X., Cheng, L., Xu, X., Fan, Z., Zhang, J., Ye, Q., and Song, H. (2014) MiR-410 is overexpressed in liver and colorectal tumors and enhances tumor cell growth by silencing FHL1 via a direct/indirect mechanism. PLoS One 9, e108708.
43. Wu, Q., Liu, H.-O., Liu, Y.-D., Liu, W.-S., Pan, D., Zhang, W.-J., Yang, L., Fu, Q., Xu, J.-J., and Gu, J.-X. (2015) Decreased expression of hepatocyte nuclear factor 4a (Hnf4a)/microRNA-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity. J. Biol. Chem. 290, 1170-1185.
44. Xu, H., He, J.-H., Xiao, Z.-D., Zhang, Q.-Q., Chen, Y.-Q., Zhou, H., and Qu, L.-H. (2010) Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 52, 1431-1442.